study_no,PMID,title,country,setting,study_type,abx_tx_site,colonisation_site,abx_type,abx_route,resistance_type,bacteria_reported,cluster_rand,n_cluster,abx_dur,n_ind_contributedsamples,n_sample,time_baseline_endoffu,los,n_ind_outcome,n_possample_outcome,comments,,,,,,,
1,19118302,Decontamination of the digestive tract and oropharynx in ICU patients,Netherlands,ICU,SDD,Gut,Gut,NA,NA,Aminoglycoside,Gram negatives,1,13,0,171,1028,Point prevalence surveys,9,10,Not reported,"The use of antibiotics with antianaerobic activity, such as amoxicillin, penicillin, amoxicillin–clavulanic acid, and carbapenems, was discouraged during the SDD period. Surveillance cultures of endotracheal aspirates and oropharyngeal and rectal swabs we",,,,,,,
1,19118302,Decontamination of the digestive tract and oropharynx in ICU patients,Netherlands,ICU,SDD,Gut,Gut,NA,NA,Fluoroquinolone,Gram negatives,1,13,0,171,1028,Point prevalence surveys,9,10.8,Not reported,"los = length of stay, will be used to calculate time at risk",,,,,,,
1,19118302,Decontamination of the digestive tract and oropharynx in ICU patients,Netherlands,ICU,SDD,Gut,Gut,NA,NA,Cephalosporin,Gram negatives,1,13,0,171,1028,Point prevalence surveys,9,12.82,Not reported,"Because surveillance was done in ICU, los for ICU is taken",,,,,,,
1,19118302,Decontamination of the digestive tract and oropharynx in ICU patients,Netherlands,ICU,SDD,Gut,Gut,NA,NA,Multiresistant,Gram negatives,1,13,0,171,1028,Point prevalence surveys,9,7.1,Not reported,,,,,,,,
1,19118302,Decontamination of the digestive tract and oropharynx in ICU patients,Netherlands,ICU,SDD,Gut,Gut,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Aminoglycoside,Gram negatives,1,13,4,165,988,Point prevalence surveys,9,4.1,Not reported,,,,,,,,
1,19118302,Decontamination of the digestive tract and oropharynx in ICU patients,Netherlands,ICU,SDD,Gut,Gut,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Fluoroquinolone,Gram negatives,1,13,4,165,988,Point prevalence surveys,9,4.8,Not reported,,,,,,,,
1,19118302,Decontamination of the digestive tract and oropharynx in ICU patients,Netherlands,ICU,SDD,Gut,Gut,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Cephalosporin,Gram negatives,1,13,4,165,988,Point prevalence surveys,9,4.12,Not reported,,,,,,,,
1,19118302,Decontamination of the digestive tract and oropharynx in ICU patients,Netherlands,ICU,SDD,Gut,Gut,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Multiresistant,Gram negatives,1,13,4,165,988,Point prevalence surveys,9,3.4,Not reported,,,,,,,,
1,19118302,Decontamination of the digestive tract and oropharynx in ICU patients,Netherlands,ICU,SDD,Gut,Respiratory tract,NA,NA,Aminoglycoside,Gram negatives,1,13,0,149,891,Point prevalence surveys,9,7.4,Not reported,,,,,,,,
1,19118302,Decontamination of the digestive tract and oropharynx in ICU patients,Netherlands,ICU,SDD,Gut,Respiratory tract,NA,NA,Fluoroquinolone,Gram negatives,1,13,0,149,891,Point prevalence surveys,9,8.2,Not reported,,,,,,,,
1,19118302,Decontamination of the digestive tract and oropharynx in ICU patients,Netherlands,ICU,SDD,Gut,Respiratory tract,NA,NA,Cephalosporin,Gram negatives,1,13,0,149,891,Point prevalence surveys,9,10.2,Not reported,,,,,,,,
1,19118302,Decontamination of the digestive tract and oropharynx in ICU patients,Netherlands,ICU,SDD,Gut,Respiratory tract,NA,NA,Multiresistant,Gram negatives,1,13,0,149,891,Point prevalence surveys,9,7.1,Not reported,,,,,,,,
1,19118302,Decontamination of the digestive tract and oropharynx in ICU patients,Netherlands,ICU,SDD,Gut,Respiratory tract,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Aminoglycoside,Gram negatives,1,13,4,149,894,Point prevalence surveys,9,12.6,Not reported,,,,,,,,
1,19118302,Decontamination of the digestive tract and oropharynx in ICU patients,Netherlands,ICU,SDD,Gut,Respiratory tract,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Fluoroquinolone,Gram negatives,1,13,4,149,894,Point prevalence surveys,9,1.9,Not reported,,,,,,,,
1,19118302,Decontamination of the digestive tract and oropharynx in ICU patients,Netherlands,ICU,SDD,Gut,Respiratory tract,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Cephalosporin,Gram negatives,1,13,4,149,894,Point prevalence surveys,9,1.6,Not reported,,,,,,,,
1,19118302,Decontamination of the digestive tract and oropharynx in ICU patients,Netherlands,ICU,SDD,Gut,Respiratory tract,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Multiresistant,Gram negatives,1,13,4,149,894,Point prevalence surveys,9,1,Not reported,,,,,,,,
2,18454864,"Antimicrobial treatment for ventilator-associated tracheobronchitis: a randomized, controlled, multicenter study",France,ICU,Treatment for infection,Respiratory tract,Respiratory tract,NA,NA,Ceftazidime or imipenem-resistant,Gram negatives,0,NA,0,26,Not reported,36,NA,5,Not reported,followed up until ICU discharge or 28 days after random assignment if they were discharged from the ICU before,,,,,,,
2,18454864,"Antimicrobial treatment for ventilator-associated tracheobronchitis: a randomized, controlled, multicenter study",France,ICU,Treatment for infection,Respiratory tract,Respiratory tract,NA,NA,Meticillin,Staph aureus,0,NA,0,26,Not reported,36,NA,0,Not reported,Used length of ICU tsays reported in table 6,,,,,,,
2,18454864,"Antimicrobial treatment for ventilator-associated tracheobronchitis: a randomized, controlled, multicenter study",France,ICU,Treatment for infection,Respiratory tract,Respiratory tract,NA,NA,ESBL-producing ,Gram negatives,0,NA,0,26,Not reported,36,NA,3,Not reported,,,,,,,,
2,18454864,"Antimicrobial treatment for ventilator-associated tracheobronchitis: a randomized, controlled, multicenter study",France,ICU,Treatment for infection,Respiratory tract,Respiratory tract,Culture directed,IV,Ceftazidime or imipenem-resistant,Gram negatives,0,NA,8,18,Not reported,40,NA,3,Not reported,,,,,,,,
2,18454864,"Antimicrobial treatment for ventilator-associated tracheobronchitis: a randomized, controlled, multicenter study",France,ICU,Treatment for infection,Respiratory tract,Respiratory tract,Culture directed,IV,Meticillin,Staph aureus,0,NA,8,18,Not reported,40,NA,1,Not reported,,,,,,,,
2,18454864,"Antimicrobial treatment for ventilator-associated tracheobronchitis: a randomized, controlled, multicenter study",France,ICU,Treatment for infection,Respiratory tract,Respiratory tract,Culture directed,IV,ESBL-producing ,Gram negatives,0,NA,8,18,Not reported,40,NA,2,Not reported,,,,,,,,
3,11434826,"Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial",Dominican Republic,Outpatient,Treatment for infection,Respiratory tract,Respiratory tract,NA,NA,Penicillin,Pneumococcus,0,NA,0,795,Not reported,1,NA,210,Not reported,Baseline,,,,,,,
3,11434826,"Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial",Dominican Republic,Outpatient,Treatment for infection,Respiratory tract,Respiratory tract,NA,NA,Amoxicillin,Pneumococcus,0,NA,0,795,Not reported,1,NA,3,Not reported,,,,,,,,
3,11434826,"Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial",Dominican Republic,Outpatient,Treatment for infection,Respiratory tract,Respiratory tract,NA,NA,Trimethoprim-sulfamethoxazole,Pneumococcus,0,NA,0,795,Not reported,1,NA,157,Not reported,,,,,,,,
3,11434826,"Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial",Dominican Republic,Outpatient,Treatment for infection,Respiratory tract,Respiratory tract,Amoxicillin,Oral,Penicillin,Pneumococcus,0,NA,5,740,Not reported,5,NA,151.65,Not reported,,,,,,,,
3,11434826,"Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial",Dominican Republic,Outpatient,Treatment for infection,Respiratory tract,Respiratory tract,Amoxicillin,Oral,Penicillin,Pneumococcus,0,NA,5,364,Not reported,10,NA,83.72,Not reported,,,,,,,,
3,11434826,"Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial",Dominican Republic,Outpatient,Treatment for infection,Respiratory tract,Respiratory tract,Amoxicillin,Oral,Penicillin,Pneumococcus,0,NA,10,358,Not reported,10,NA,71.6,Not reported,,,,,,,,
3,11434826,"Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial",Dominican Republic,Outpatient,Treatment for infection,Respiratory tract,Respiratory tract,Amoxicillin,Oral,Penicillin,Pneumococcus,0,NA,5,355,Not reported,28,NA,85.2,Not reported,,,,,,,,
3,11434826,"Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial",Dominican Republic,Outpatient,Treatment for infection,Respiratory tract,Respiratory tract,Amoxicillin,Oral,Penicillin,Pneumococcus,0,NA,10,346,Not reported,28,NA,110.72,Not reported,,,,,,,,
3,11434826,"Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial",Dominican Republic,Outpatient,Treatment for infection,Respiratory tract,Respiratory tract,Amoxicillin,Oral,Trimethoprim-sulfamethoxazole,Pneumococcus,0,NA,5,355,Not reported,28,NA,62,Not reported,,,,,,,,
3,11434826,"Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial",Dominican Republic,Outpatient,Treatment for infection,Respiratory tract,Respiratory tract,Amoxicillin,Oral,Trimethoprim-sulfamethoxazole,Pneumococcus,0,NA,10,346,Not reported,28,NA,81,Not reported,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Treatment for infection,Urinary tract,Urine,NA,NA,Amoxicillin,E coli,0,NA,0,60,60,1,NA,5,5,"to receive either a 3-day antibiotic treatment associated with indwelling urethral catheter replacement 4 h after the first administration of antibiotic (i.e. the study group) or no antibiotic, no catheter replacement (i.e. standard of care). Antibiotics ",,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Treatment for infection,Urinary tract,Urine,NA,NA,Amoxicillin,E coli,0,NA,0,30,30,7,NA,2,2,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Treatment for infection,Urinary tract,Urine,Culture directed,Oral or IV,Amoxicillin,E coli,0,NA,3,30,30,7,NA,2,2,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Treatment for infection,Urinary tract,Urine,NA,NA,Amoxicillin,E coli,0,NA,0,30,30,15,NA,0,0,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Treatment for infection,Urinary tract,Urine,Culture directed,Oral or IV,Amoxicillin,E coli,0,NA,3,30,30,15,NA,2,2,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Treatment for infection,Urinary tract,Urine,NA,NA,Amox-clav,E coli,0,NA,0,60,60,1,NA,6,6,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Treatment for infection,Urinary tract,Urine,NA,NA,Amox-clav,E coli,0,NA,0,30,30,7,NA,0,0,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Treatment for infection,Urinary tract,Urine,Culture directed,Oral or IV,Amox-clav,E coli,0,NA,3,30,30,7,NA,1,1,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Treatment for infection,Urinary tract,Urine,NA,NA,Amox-clav,E coli,0,NA,0,30,30,15,NA,0,0,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Treatment for infection,Urinary tract,Urine,Culture directed,Oral or IV,Amox-clav,E coli,0,NA,3,30,30,15,NA,0,0,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Treatment for infection,Urinary tract,Urine,NA,NA,Ticacillin,Pseudomonas,0,NA,0,60,60,1,NA,8,8,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Treatment for infection,Urinary tract,Urine,NA,NA,Ticacillin,Pseudomonas,0,NA,0,30,30,7,NA,4,4,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Treatment for infection,Urinary tract,Urine,Culture directed,Oral or IV,Ticacillin,Pseudomonas,0,NA,3,30,30,7,NA,1,1,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Treatment for infection,Urinary tract,Urine,NA,NA,Ticacillin,Pseudomonas,0,NA,0,30,30,15,NA,1,1,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Treatment for infection,Urinary tract,Urine,Culture directed,Oral or IV,Ticacillin,Pseudomonas,0,NA,3,30,30,15,NA,2,2,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Treatment for infection,Urinary tract,Urine,NA,NA,Ticacillin,Acinectobacter baumannii,0,NA,0,60,60,1,NA,3,3,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Treatment for infection,Urinary tract,Urine,NA,NA,Ticacillin,Acinectobacter baumannii,0,NA,0,30,30,7,NA,0,0,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Treatment for infection,Urinary tract,Urine,Culture directed,Oral or IV,Ticacillin,Acinectobacter baumannii,0,NA,3,30,30,7,NA,1,1,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Treatment for infection,Urinary tract,Urine,NA,NA,Ticacillin,Acinectobacter baumannii,0,NA,0,30,30,15,NA,0,0,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Treatment for infection,Urinary tract,Urine,Culture directed,Oral or IV,Ticacillin,Acinectobacter baumannii,0,NA,3,30,30,15,NA,1,1,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Treatment for infection,Urinary tract,Urine,NA,NA,Amox-clav,Klebsiella pneumoniae,0,NA,0,60,60,1,NA,5,5,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Treatment for infection,Urinary tract,Urine,NA,NA,Amox-clav,Klebsiella pneumoniae,0,NA,0,30,30,7,NA,1,1,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Treatment for infection,Urinary tract,Urine,Culture directed,Oral or IV,Amox-clav,Klebsiella pneumoniae,0,NA,3,30,30,7,NA,0,0,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Treatment for infection,Urinary tract,Urine,NA,NA,Amox-clav,Klebsiella pneumoniae,0,NA,0,30,30,15,NA,1,1,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Treatment for infection,Urinary tract,Urine,Culture directed,Oral or IV,Amox-clav,Klebsiella pneumoniae,0,NA,3,30,30,15,NA,1,1,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Treatment for infection,Urinary tract,Urine,NA,NA,Cefotaxime,Citrobacter,0,NA,0,60,60,1,NA,0,0,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Treatment for infection,Urinary tract,Urine,NA,NA,Cefotaxime,Citrobacter,0,NA,0,30,30,7,NA,0,0,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Treatment for infection,Urinary tract,Urine,Culture directed,Oral or IV,Cefotaxime,Citrobacter,0,NA,3,30,30,7,NA,1,0,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Treatment for infection,Urinary tract,Urine,NA,NA,Cefotaxime,Citrobacter,0,NA,0,30,30,15,NA,0,0,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Treatment for infection,Urinary tract,Urine,Culture directed,Oral or IV,Cefotaxime,Citrobacter,0,NA,3,30,30,15,NA,0,0,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Treatment for infection,Urinary tract,Urine,NA,NA,Amoxicillin,Enterococcus,0,NA,0,60,60,1,NA,8,8,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Treatment for infection,Urinary tract,Urine,NA,NA,Amoxicillin,Enterococcus,0,NA,0,30,30,7,NA,2,2,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Treatment for infection,Urinary tract,Urine,Culture directed,Oral or IV,Amoxicillin,Enterococcus,0,NA,3,30,30,7,NA,1,1,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Treatment for infection,Urinary tract,Urine,NA,NA,Amoxicillin,Enterococcus,0,NA,0,30,30,15,NA,1,1,,,,,,,,
5,24461664,"Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial",Australia/NZ,Outpatient,Prophylaxis,Respiratory tract,Respiratory tract,NA,NA,Ampicillin,M catarhalis,0,NA,0,78,78,1,NA,10,10,,,,,,,,
5,24461664,"Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial",Australia/NZ,Outpatient,Prophylaxis,Respiratory tract,Respiratory tract,NA,NA,Ampicillin,M catarhalis,0,NA,0,37,78,720,NA,5,5,,,,,,,,
5,24461664,"Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial",Australia/NZ,Outpatient,Prophylaxis,Respiratory tract,Respiratory tract,Azithromycin,Oral,Ampicillin,M catarhalis,0,NA,once weekly for 24 months,41,78,720,NA,0,0,,,,,,,,
5,24461664,"Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial",Australia/NZ,Outpatient,Prophylaxis,Respiratory tract,Respiratory tract,NA,NA,Azithromycin,Staph aureus,0,NA,0,78,78,1,NA,7,7,,,,,,,,
5,24461664,"Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial",Australia/NZ,Outpatient,Prophylaxis,Respiratory tract,Respiratory tract,NA,NA,Meticillin,Staph aureus,0,NA,0,78,78,1,NA,2,2,,,,,,,,
5,24461664,"Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial",Australia/NZ,Outpatient,Prophylaxis,Respiratory tract,Respiratory tract,NA,NA,Azithromycin,Staph aureus,0,NA,0,37,78,720,NA,3,3,,,,,,,,
5,24461664,"Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial",Australia/NZ,Outpatient,Prophylaxis,Respiratory tract,Respiratory tract,NA,NA,Meticillin,Staph aureus,0,NA,0,37,78,720,NA,1,1,,,,,,,,
5,24461664,"Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial",Australia/NZ,Outpatient,Prophylaxis,Respiratory tract,Respiratory tract,Azithromycin,Oral,Azithromycin,Staph aureus,0,NA,once weekly for 24 months,41,78,720,NA,11,11,,,,,,,,
5,24461664,"Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial",Australia/NZ,Outpatient,Prophylaxis,Respiratory tract,Respiratory tract,Azithromycin,Oral,Meticillin,Staph aureus,0,NA,once weekly for 24 months,41,78,720,NA,2,2,,,,,,,,
5,24461664,"Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial",Australia/NZ,Outpatient,Prophylaxis,Respiratory tract,Respiratory tract,NA,NA,Azithromycin,H influenzae,0,NA,0,78,78,1,NA,1,1,,,,,,,,
5,24461664,"Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial",Australia/NZ,Outpatient,Prophylaxis,Respiratory tract,Respiratory tract,NA,NA,Ampicillin,H influenzae,0,NA,0,78,78,1,NA,4,4,,,,,,,,
5,24461664,"Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial",Australia/NZ,Outpatient,Prophylaxis,Respiratory tract,Respiratory tract,NA,NA,Azithromycin,H influenzae,0,NA,0,37,78,720,NA,0,0,,,,,,,,
5,24461664,"Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial",Australia/NZ,Outpatient,Prophylaxis,Respiratory tract,Respiratory tract,NA,NA,Ampicillin,H influenzae,0,NA,0,37,78,720,NA,1,1,,,,,,,,
5,24461664,"Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial",Australia/NZ,Outpatient,Prophylaxis,Respiratory tract,Respiratory tract,Azithromycin,Oral,Azithromycin,H influenzae,0,NA,once weekly for 24 months,41,78,720,NA,0,0,,,,,,,,
5,24461664,"Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial",Australia/NZ,Outpatient,Prophylaxis,Respiratory tract,Respiratory tract,Azithromycin,Oral,Ampicillin,H influenzae,0,NA,once weekly for 24 months,41,78,720,NA,1,1,,,,,,,,
5,24461664,"Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial",Australia/NZ,Outpatient,Prophylaxis,Respiratory tract,Respiratory tract,NA,NA,Azithromycin,Pneumococcus,0,NA,0,78,78,1,NA,11,11,,,,,,,,
5,24461664,"Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial",Australia/NZ,Outpatient,Prophylaxis,Respiratory tract,Respiratory tract,NA,NA,Penicillin,Pneumococcus,0,NA,0,78,78,1,NA,13,13,,,,,,,,
5,24461664,"Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial",Australia/NZ,Outpatient,Prophylaxis,Respiratory tract,Respiratory tract,NA,NA,Azithromycin,Pneumococcus,0,NA,0,37,78,720,NA,1,1,,,,,,,,
5,24461664,"Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial",Australia/NZ,Outpatient,Prophylaxis,Respiratory tract,Respiratory tract,NA,NA,Penicillin,Pneumococcus,0,NA,0,37,78,720,NA,6,6,,,,,,,,
5,24461664,"Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial",Australia/NZ,Outpatient,Prophylaxis,Respiratory tract,Respiratory tract,Azithromycin,Oral,Azithromycin,Pneumococcus,0,NA,once weekly for 24 months,41,78,720,NA,11,11,,,,,,,,
5,24461664,"Long-term azithromycin for Indigenous children with non-cystic-fibrosis bronchiectasis or chronic suppurative lung disease (Bronchiectasis Intervention Study): a multicentre, double-blind, randomised controlled trial",Australia/NZ,Outpatient,Prophylaxis,Respiratory tract,Respiratory tract,Azithromycin,Oral,Penicillin,Pneumococcus,0,NA,once weekly for 24 months,41,78,720,NA,6,6,,,,,,,,
6,17484870,High-dose oral erythromycin decreased the incidence of parenteral nutrition-associated cholestasis in preterm infants,Hong Kong,Neonatal unit,Prevention or treatment of non-infectious diseases,Gut,Gut,NA,NA,Meticillin,Staph aureus,0,NA,0,75,75,1,NA,0,0,"Stool samples for microbiologic culture were collected from the studied infants immediately before treatment, after 10 days of medication, and 4 weeks after the treatment had been terminated.",,,,,,,
6,17484870,High-dose oral erythromycin decreased the incidence of parenteral nutrition-associated cholestasis in preterm infants,Hong Kong,Neonatal unit,Prevention or treatment of non-infectious diseases,Gut,Gut,NA,NA,Meticillin,Staph aureus,0,NA,0,38,38,10,NA,1,1,,,,,,,,
6,17484870,High-dose oral erythromycin decreased the incidence of parenteral nutrition-associated cholestasis in preterm infants,Hong Kong,Neonatal unit,Prevention or treatment of non-infectious diseases,Gut,Gut,Erythromycin,Oral,Meticillin,Staph aureus,0,NA,10,37,37,10,NA,0,0,,,,,,,,
6,17484870,High-dose oral erythromycin decreased the incidence of parenteral nutrition-associated cholestasis in preterm infants,Hong Kong,Neonatal unit,Prevention or treatment of non-infectious diseases,Gut,Gut,NA,NA,Meticillin,Staph aureus,0,NA,0,38,38,42,NA,0,0,,,,,,,,
6,17484870,High-dose oral erythromycin decreased the incidence of parenteral nutrition-associated cholestasis in preterm infants,Hong Kong,Neonatal unit,Prevention or treatment of non-infectious diseases,Gut,Gut,Erythromycin,Oral,Meticillin,Staph aureus,0,NA,14,37,37,42,NA,0,0,,,,,,,,
7,15356779,"A prospective, randomized trial of 3 or 14 days of ciprofloxacin treatment for acute urinary tract infection in patients with spinal cord injury",Canada,Outpatient,Treatment for infection,Urinary tract,Urine,Ciprofloxacin,Oral,Fluoroquinolone,Gram negatives,0,NA,3,30,30,42,NA,8,8,"Eight patients (27%) who received treatment for 3 days and 5 patients (17%) who received treatment for 14 days became colonized with a new ciprofloxacin-resistant organism in the urinary tract, on a mucosal surface, or in both locations. These resistant s",,,,,,,
7,15356779,"A prospective, randomized trial of 3 or 14 days of ciprofloxacin treatment for acute urinary tract infection in patients with spinal cord injury",Canada,Outpatient,Treatment for infection,Urinary tract,Urine,Ciprofloxacin,Oral,Fluoroquinolone,Gram negatives,0,NA,14,30,30,42,NA,5,5,But did not specify the groups,,,,,,,
8,28002709,Shortened Antimicrobial Treatment for Acute Otitis Media in Young Children,USA,Outpatient,Treatment for infection,Inner ear,Respiratory tract,NA,NA,Penicillin,Pneumococcus,0,NA,0,514,514,1,NA,85,85,,,,,,,,
8,28002709,Shortened Antimicrobial Treatment for Acute Otitis Media in Young Children,USA,Outpatient,Treatment for infection,Inner ear,Respiratory tract,NA,NA,Beta-lactamase producing,H influenzae,0,NA,0,514,514,1,NA,55,55,,,,,,,,
8,28002709,Shortened Antimicrobial Treatment for Acute Otitis Media in Young Children,USA,Outpatient,Treatment for infection,Inner ear,Respiratory tract,Amox-clav,Oral,Penicillin,Pneumococcus,0,NA,5,222,222,14,NA,26,26,"Only included carriage data at the end-of treatment assessment and not after because did not define when the final visits were for the patients (""typically following year September"")",,,,,,,
8,28002709,Shortened Antimicrobial Treatment for Acute Otitis Media in Young Children,USA,Outpatient,Treatment for infection,Inner ear,Respiratory tract,Amox-clav,Oral,Beta-lactamase producing,H influenzae,0,NA,5,222,222,14,NA,28,28,,,,,,,,
8,28002709,Shortened Antimicrobial Treatment for Acute Otitis Media in Young Children,USA,Outpatient,Treatment for infection,Inner ear,Respiratory tract,Amox-clav,Oral,Penicillin,Pneumococcus,0,NA,10,233,233,14,NA,23,23,,,,,,,,
8,28002709,Shortened Antimicrobial Treatment for Acute Otitis Media in Young Children,USA,Outpatient,Treatment for infection,Inner ear,Respiratory tract,Amox-clav,Oral,Beta-lactamase producing,H influenzae,0,NA,10,233,233,14,NA,38,38,,,,,,,,
9,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,SDD,Gut,Gut and respiratory tract,NA,NA,Ceftazidime ,Pseudomonas,1,2,0,868,868,1,NA,2,2,,,,,,,,
9,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,SDD,Gut,Gut and respiratory tract,NA,NA,Ciprofloxacin,Pseudomonas,1,2,0,868,868,1,NA,1,1,,,,,,,,
9,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,SDD,Gut,Gut and respiratory tract,NA,NA,Imipenem,Pseudomonas,1,2,0,868,868,1,NA,0,0,,,,,,,,
9,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,SDD,Gut,Gut and respiratory tract,NA,NA,Polymyxin,Pseudomonas,1,2,0,868,868,1,NA,0,0,,,,,,,,
9,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,SDD,Gut,Gut and respiratory tract,NA,NA,Tobramycin,Pseudomonas,1,2,0,868,868,1,NA,2,2,,,,,,,,
9,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,SDD,Gut,Gut and respiratory tract,NA,NA,Ceftazidime ,Gram negatives,1,2,0,868,868,1,NA,5,5,,,,,,,,
9,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,SDD,Gut,Gut and respiratory tract,NA,NA,Ciprofloxacin,Gram negatives,1,2,0,868,868,1,NA,28,28,,,,,,,,
9,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,SDD,Gut,Gut and respiratory tract,NA,NA,Imipenem,Gram negatives,1,2,0,868,868,1,NA,2,2,,,,,,,,
9,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,SDD,Gut,Gut and respiratory tract,NA,NA,Polymyxin,Gram negatives,1,2,0,868,868,1,NA,0,0,,,,,,,,
9,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,SDD,Gut,Gut and respiratory tract,NA,NA,Tobramycin,Gram negatives,1,2,0,868,868,1,NA,45,45,,,,,,,,
9,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,SDD,Gut,Gut and respiratory tract,NA,NA,Vancomycin,Enterococcus,1,2,0,868,868,1,NA,10,10,,,,,,,,
9,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,SDD,Gut,Gut and respiratory tract,NA,NA,Meticillin,Staph aureus,1,2,0,868,868,1,NA,0,0,"Colonisation with resistant bacteria from sputum, throat, rectum, axilla, and wounds was assessed at the time of ICU admission, once weekly during the stay, at discharge from the ICU, and, if possible, at 7 days after ICU discharge.",,,,,,,
9,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,SDD,Gut,Gut and respiratory tract,NA,NA,Ceftazidime ,Pseudomonas,1,2,0,395,Not reported,15.5,NA,12,Not reported,Median ICU length of stay was 6·8 days (IQR 3·7–12·8) in the SDD group compared with 8·5 days (4·8–15·7) in the control group (p<0·0001).,,,,,,,
9,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,SDD,Gut,Gut and respiratory tract,NA,NA,Ciprofloxacin,Pseudomonas,1,2,0,395,Not reported,15.5,NA,13,Not reported,Hence use 13.8 days for SDD and 15.5 for control,,,,,,,
9,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,SDD,Gut,Gut and respiratory tract,NA,NA,Imipenem,Pseudomonas,1,2,0,395,Not reported,15.5,NA,16,Not reported,,,,,,,,
9,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,SDD,Gut,Gut and respiratory tract,NA,NA,Polymyxin,Pseudomonas,1,2,0,395,Not reported,15.5,NA,0,Not reported,,,,,,,,
9,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,SDD,Gut,Gut and respiratory tract,NA,NA,Tobramycin,Pseudomonas,1,2,0,395,Not reported,15.5,NA,13,Not reported,,,,,,,,
9,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,SDD,Gut,Gut and respiratory tract,NA,NA,Ceftazidime ,Gram negatives,1,2,0,395,Not reported,15.5,NA,9,Not reported,,,,,,,,
9,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,SDD,Gut,Gut and respiratory tract,NA,NA,Ciprofloxacin,Gram negatives,1,2,0,395,Not reported,15.5,NA,31,Not reported,,,,,,,,
9,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,SDD,Gut,Gut and respiratory tract,NA,NA,Imipenem,Gram negatives,1,2,0,395,Not reported,15.5,NA,10,Not reported,,,,,,,,
9,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,SDD,Gut,Gut and respiratory tract,NA,NA,Polymyxin,Gram negatives,1,2,0,395,Not reported,15.5,NA,2,Not reported,,,,,,,,
9,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,SDD,Gut,Gut and respiratory tract,NA,NA,Tobramycin,Gram negatives,1,2,0,395,Not reported,15.5,NA,47,Not reported,,,,,,,,
9,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,SDD,Gut,Gut and respiratory tract,NA,NA,Vancomycin,Enterococcus,1,2,0,395,Not reported,15.5,NA,5,Not reported,,,,,,,,
9,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,SDD,Gut,Gut and respiratory tract,NA,NA,Meticillin,Staph aureus,1,2,0,395,Not reported,15.5,NA,0,Not reported,,,,,,,,
9,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,SDD,Gut,Gut and respiratory tract,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Ceftazidime ,Pseudomonas,1,2,4,378,Not reported,13.8,NA,2,Not reported,,,,,,,,
9,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,SDD,Gut,Gut and respiratory tract,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Ciprofloxacin,Pseudomonas,1,2,4,378,Not reported,13.8,NA,1,Not reported,,,,,,,,
9,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,SDD,Gut,Gut and respiratory tract,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Imipenem,Pseudomonas,1,2,4,378,Not reported,13.8,NA,1,Not reported,,,,,,,,
9,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,SDD,Gut,Gut and respiratory tract,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Polymyxin,Pseudomonas,1,2,4,378,Not reported,13.8,NA,1,Not reported,,,,,,,,
9,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,SDD,Gut,Gut and respiratory tract,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Tobramycin,Pseudomonas,1,2,4,378,Not reported,13.8,NA,13,Not reported,,,,,,,,
9,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,SDD,Gut,Gut and respiratory tract,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Ceftazidime ,Gram negatives,1,2,4,378,Not reported,13.8,NA,7,Not reported,,,,,,,,
9,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,SDD,Gut,Gut and respiratory tract,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Ciprofloxacin,Gram negatives,1,2,4,378,Not reported,13.8,NA,9,Not reported,,,,,,,,
9,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,SDD,Gut,Gut and respiratory tract,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Imipenem,Gram negatives,1,2,4,378,Not reported,13.8,NA,1,Not reported,,,,,,,,
9,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,SDD,Gut,Gut and respiratory tract,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Polymyxin,Gram negatives,1,2,4,378,Not reported,13.8,NA,3,Not reported,,,,,,,,
9,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,SDD,Gut,Gut and respiratory tract,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Tobramycin,Gram negatives,1,2,4,378,Not reported,13.8,NA,20,Not reported,,,,,,,,
9,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,SDD,Gut,Gut and respiratory tract,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Vancomycin,Enterococcus,1,2,4,378,Not reported,13.8,NA,4,Not reported,,,,,,,,
9,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,SDD,Gut,Gut and respiratory tract,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Meticillin,Staph aureus,1,2,4,378,Not reported,13.8,NA,0,Not reported,,,,,,,,
10,25271544,Effects of Decontamination of the Oropharynx and Intestinal Tract on Antibiotic Resistance in ICUs: A Randomized Clinical Trial,Netherlands,ICU,SDD,Gut,Gut,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Multiresistant,Gram negatives,1,16,4,1928,3776,Point prevalence surveys,6,140,Not reported,There were 384 point-prevalence surveys yielding 3776 rectal swabs,,,,,,,
10,25271544,Effects of Decontamination of the Oropharynx and Intestinal Tract on Antibiotic Resistance in ICUs: A Randomized Clinical Trial,Netherlands,ICU,SDD,Gut,Gut,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,ESBL-producing ,Gram negatives,1,16,4,1928,3776,Point prevalence surveys,6,85,Not reported,Baseline prevalence not reported,,,,,,,
10,25271544,Effects of Decontamination of the Oropharynx and Intestinal Tract on Antibiotic Resistance in ICUs: A Randomized Clinical Trial,Netherlands,ICU,SDD,Gut,Gut,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Aminoglycoside,Gram negatives,1,16,4,1928,3776,Point prevalence surveys,6,109,Not reported,,,,,,,,
10,25271544,Effects of Decontamination of the Oropharynx and Intestinal Tract on Antibiotic Resistance in ICUs: A Randomized Clinical Trial,Netherlands,ICU,SDD,Gut,Gut,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Ciprofloxacin,Gram negatives,1,16,4,1928,3776,Point prevalence surveys,6,108,Not reported,,,,,,,,
10,25271544,Effects of Decontamination of the Oropharynx and Intestinal Tract on Antibiotic Resistance in ICUs: A Randomized Clinical Trial,Netherlands,ICU,SDD,Gut,Gut,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Carbapenem,Gram negatives,1,16,4,1928,3776,Point prevalence surveys,6,30,Not reported,,,,,,,,
10,25271544,Effects of Decontamination of the Oropharynx and Intestinal Tract on Antibiotic Resistance in ICUs: A Randomized Clinical Trial,Netherlands,ICU,SDD,Gut,Gut,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Colistin,Gram negatives,1,16,4,1928,3776,Point prevalence surveys,6,23,Not reported,,,,,,,,
10,25271544,Effects of Decontamination of the Oropharynx and Intestinal Tract on Antibiotic Resistance in ICUs: A Randomized Clinical Trial,Netherlands,ICU,SDD,Gut,Gut,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Vancomycin,Enterococcus,1,16,4,1928,3776,Point prevalence surveys,6,11,Not reported,,,,,,,,
10,25271544,Effects of Decontamination of the Oropharynx and Intestinal Tract on Antibiotic Resistance in ICUs: A Randomized Clinical Trial,Netherlands,ICU,SDD,Gut,Respiratory tract,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Multiresistant,Not reported,1,16,4,1840,Not reported,Point prevalence surveys,6,47,Not reported,,,,,,,,
10,25271544,Effects of Decontamination of the Oropharynx and Intestinal Tract on Antibiotic Resistance in ICUs: A Randomized Clinical Trial,Netherlands,ICU,SDD,Gut,Respiratory tract,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,ESBL-producing ,Not reported,1,16,4,1840,Not reported,Point prevalence surveys,6,24,Not reported,,,,,,,,
10,25271544,Effects of Decontamination of the Oropharynx and Intestinal Tract on Antibiotic Resistance in ICUs: A Randomized Clinical Trial,Netherlands,ICU,SDD,Gut,Respiratory tract,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Aminoglycoside,Not reported,1,16,4,1840,Not reported,Point prevalence surveys,6,50,Not reported,,,,,,,,
10,25271544,Effects of Decontamination of the Oropharynx and Intestinal Tract on Antibiotic Resistance in ICUs: A Randomized Clinical Trial,Netherlands,ICU,SDD,Gut,Respiratory tract,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Ciprofloxacin,Not reported,1,16,4,1840,Not reported,Point prevalence surveys,6,46,Not reported,,,,,,,,
10,25271544,Effects of Decontamination of the Oropharynx and Intestinal Tract on Antibiotic Resistance in ICUs: A Randomized Clinical Trial,Netherlands,ICU,SDD,Gut,Respiratory tract,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Carbapenem,Not reported,1,16,4,1840,Not reported,Point prevalence surveys,6,15,Not reported,,,,,,,,
10,25271544,Effects of Decontamination of the Oropharynx and Intestinal Tract on Antibiotic Resistance in ICUs: A Randomized Clinical Trial,Netherlands,ICU,SDD,Gut,Respiratory tract,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Colistin,Not reported,1,16,4,1840,Not reported,Point prevalence surveys,6,12,Not reported,,,,,,,,
11,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,SDD,Gut,Gut,NA,NA,ESBL-producing ,Gram negatives,1,26,0,1456,1392,Point prevalence surveys,7,230.048,Not reported,No length of stay reported in main and supplementary  but same setting as the previous 2 ICU decontamination studies. Assume to be 7 ,,,,,,,
11,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,SDD,Gut,Gut,NA,NA,Carbapenem,Gram negatives,1,26,0,1456,1392,Point prevalence surveys,7,46.592,Not reported,,,,,,,,
11,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,SDD,Gut,Gut,NA,NA,Multiresistant,Gram negatives,1,26,0,1456,1392,Point prevalence surveys,7,157.248,Not reported,,,,,,,,
11,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,SDD,Gut,Gut,NA,NA,Colistin,Gram negatives,1,26,0,1456,1392,Point prevalence surveys,7,7.28,Not reported,,,,,,,,
11,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,SDD,Gut,Gut,NA,NA,Multiresistant,Non fermenters,1,26,0,1456,1392,Point prevalence surveys,7,46.592,Not reported,,,,,,,,
11,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,SDD,Gut,Gut,NA,NA,Vancomycin,Enterococcus,1,26,0,1456,1392,Point prevalence surveys,7,32.032,Not reported,,,,,,,,
11,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,SDD,Gut,Gut,"Combination (colistin, tobramycin, and nystatin)",Oral and IV,ESBL-producing ,Gram negatives,1,26,4,1407,1355,Point prevalence surveys,7,192.759,Not reported,,,,,,,,
11,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,SDD,Gut,Gut,"Combination (colistin, tobramycin, and nystatin)",Oral and IV,Carbapenem,Gram negatives,1,26,4,1407,1355,Point prevalence surveys,7,36.582,Not reported,,,,,,,,
11,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,SDD,Gut,Gut,"Combination (colistin, tobramycin, and nystatin)",Oral and IV,Multiresistant,Gram negatives,1,26,4,1407,1355,Point prevalence surveys,7,140.7,Not reported,,,,,,,,
11,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,SDD,Gut,Gut,"Combination (colistin, tobramycin, and nystatin)",Oral and IV,Colistin,Gram negatives,1,26,4,1407,1355,Point prevalence surveys,7,18.291,Not reported,,,,,,,,
11,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,SDD,Gut,Gut,"Combination (colistin, tobramycin, and nystatin)",Oral and IV,Multiresistant,Non fermenters,1,26,4,1407,1355,Point prevalence surveys,7,32.361,Not reported,,,,,,,,
11,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,SDD,Gut,Gut,"Combination (colistin, tobramycin, and nystatin)",Oral and IV,Vancomycin,Enterococcus,1,26,4,1407,1355,Point prevalence surveys,7,59.094,Not reported,,,,,,,,
11,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,SDD,Gut,Respiratory tract,NA,NA,ESBL-producing ,Gram negatives,1,26,0,1456,1381,Point prevalence surveys,7,93.184,Not reported,,,,,,,,
11,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,SDD,Gut,Respiratory tract,NA,NA,Carbapenem,Gram negatives,1,26,0,1456,1381,Point prevalence surveys,7,20.384,Not reported,,,,,,,,
11,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,SDD,Gut,Respiratory tract,NA,NA,Multiresistant,Gram negatives,1,26,0,1456,1381,Point prevalence surveys,7,58.24,Not reported,,,,,,,,
11,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,SDD,Gut,Respiratory tract,NA,NA,Colistin,Gram negatives,1,26,0,1456,1381,Point prevalence surveys,7,1.456,Not reported,,,,,,,,
11,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,SDD,Gut,Respiratory tract,NA,NA,Multiresistant,Non fermenters,1,26,0,1456,1381,Point prevalence surveys,7,49.504,Not reported,,,,,,,,
11,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,SDD,Gut,Respiratory tract,NA,NA,Meticillin,Staph aureus,1,26,0,1456,1381,Point prevalence surveys,7,24.752,Not reported,,,,,,,,
11,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,SDD,Gut,Respiratory tract,"Combination (colistin, tobramycin, and nystatin)",Oral and IV,ESBL-producing ,Gram negatives,1,26,4,1407,1319,Point prevalence surveys,7,63.315,Not reported,,,,,,,,
11,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,SDD,Gut,Respiratory tract,"Combination (colistin, tobramycin, and nystatin)",Oral and IV,Carbapenem,Gram negatives,1,26,4,1407,1319,Point prevalence surveys,7,7.035,Not reported,,,,,,,,
11,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,SDD,Gut,Respiratory tract,"Combination (colistin, tobramycin, and nystatin)",Oral and IV,Multiresistant,Gram negatives,1,26,4,1407,1319,Point prevalence surveys,7,49.245,Not reported,,,,,,,,
11,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,SDD,Gut,Respiratory tract,"Combination (colistin, tobramycin, and nystatin)",Oral and IV,Colistin,Gram negatives,1,26,4,1407,1319,Point prevalence surveys,7,4.221,Not reported,,,,,,,,
11,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,SDD,Gut,Respiratory tract,"Combination (colistin, tobramycin, and nystatin)",Oral and IV,Multiresistant,Non fermenters,1,26,4,1407,1319,Point prevalence surveys,7,37.989,Not reported,,,,,,,,
11,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,SDD,Gut,Respiratory tract,"Combination (colistin, tobramycin, and nystatin)",Oral and IV,Meticillin,Staph aureus,1,26,4,1407,1319,Point prevalence surveys,7,23.919,Not reported,,,,,,,,
12,16392777,Acute uncomplicated lower urinary tract infections in general practice: Clinical and microbiological cute rates after three- versus five-day treatment with trimethoprim,Netherlands,Outpatient,Treatment for infection,Urinary tract,Urine,NA,NA,Trimethoprim-sulfamethoxazole,E coli,0,NA,0,128.9583333,65.625,1,NA,13,13,,,,,,,,
12,16392777,Acute uncomplicated lower urinary tract infections in general practice: Clinical and microbiological cute rates after three- versus five-day treatment with trimethoprim,Netherlands,Outpatient,Treatment for infection,Urinary tract,Urine,Trimethoprim-sulfamethoxazole,Oral,Trimethoprim-sulfamethoxazole,E coli,0,NA,1,127.443609,127.443609,2,NA,18,18,,,,,,,,
12,16392777,Acute uncomplicated lower urinary tract infections in general practice: Clinical and microbiological cute rates after three- versus five-day treatment with trimethoprim,Netherlands,Outpatient,Treatment for infection,Urinary tract,Urine,Trimethoprim-sulfamethoxazole,Oral,Trimethoprim-sulfamethoxazole,E coli,0,NA,3,126.7857143,126.7857143,4,NA,17,17,,,,,,,,
13,18478129,Preventive antibacterial therapy in acute ischemic stroke: A randomized controlled trial,Germany,Hospital,Prophylaxis,NA,Gut,NA,NA,Fluoroquinolone,E coli,0,NA,0,59,59,1,NA,1,1,,,,,,,,
13,18478129,Preventive antibacterial therapy in acute ischemic stroke: A randomized controlled trial,Germany,Hospital,Prophylaxis,NA,Gut,NA,NA,Fluoroquinolone,E coli,0,NA,0,20,20,9,NA,1,1,,,,,,,,
13,18478129,Preventive antibacterial therapy in acute ischemic stroke: A randomized controlled trial,Germany,Hospital,Prophylaxis,NA,Gut,Moxfloxacin,IV,Fluoroquinolone,E coli,0,NA,5,20,20,9,NA,1,1,,,,,,,,
14,18513453,"Compared to placebo, long-term antibiotics resolve otitis media with effusion (OME) and prevent acute otitis media with perforation (AOMwiP) in a high-risk population: A randomized controlled trial",Australia,Outpatient,Treatment for infection,Inner ear,Respiratory tract,NA,NA,Penicillin,Pneumococcus,0,NA,0,103,103,1,NA,32.91,32.91,,,,,,,,
14,18513453,"Compared to placebo, long-term antibiotics resolve otitis media with effusion (OME) and prevent acute otitis media with perforation (AOMwiP) in a high-risk population: A randomized controlled trial",Australia,Outpatient,Treatment for infection,Inner ear,Respiratory tract,NA,NA,Beta-lactamase producing,H influenzae,0,NA,0,103,103,1,NA,4.14,4.14,,,,,,,,
14,18513453,"Compared to placebo, long-term antibiotics resolve otitis media with effusion (OME) and prevent acute otitis media with perforation (AOMwiP) in a high-risk population: A randomized controlled trial",Australia,Outpatient,Treatment for infection,Inner ear,Respiratory tract,NA,NA,Penicillin,Pneumococcus,0,NA,0,47,47,168,NA,19,19,,,,,,,,
14,18513453,"Compared to placebo, long-term antibiotics resolve otitis media with effusion (OME) and prevent acute otitis media with perforation (AOMwiP) in a high-risk population: A randomized controlled trial",Australia,Outpatient,Treatment for infection,Inner ear,Respiratory tract,Amoxicillin,Oral,Beta-lactamase producing,H influenzae,0,NA,171,50,50,168,NA,17,17,,,,,,,,
14,18513453,"Compared to placebo, long-term antibiotics resolve otitis media with effusion (OME) and prevent acute otitis media with perforation (AOMwiP) in a high-risk population: A randomized controlled trial",Australia,Outpatient,Treatment for infection,Inner ear,Respiratory tract,NA,NA,Penicillin,Pneumococcus,0,NA,0,47,47,168,NA,1,1,,,,,,,,
14,18513453,"Compared to placebo, long-term antibiotics resolve otitis media with effusion (OME) and prevent acute otitis media with perforation (AOMwiP) in a high-risk population: A randomized controlled trial",Australia,Outpatient,Treatment for infection,Inner ear,Respiratory tract,Amoxicillin,Oral,Beta-lactamase producing,H influenzae,0,NA,171,50,50,168,NA,6,6,,,,,,,,
15,18818954,Ceftibuten versus trimethoprim-sulfamethoxazole for oral treatment of febrile urinary tract infection in children,Sweden,Hospital,Treatment for infection,Urinary tract,Urine,NA,NA,Trimethoprim-sulfamethoxazole,Gram negatives,0,NA,0,128,128,1,NA,0,0,,,,,,,,
15,18818954,Ceftibuten versus trimethoprim-sulfamethoxazole for oral treatment of febrile urinary tract infection in children,Sweden,Hospital,Treatment for infection,Urinary tract,Urine,NA,NA,Ceftibuten,Gram negatives,0,NA,0,255,255,1,NA,0,0,,,,,,,,
15,18818954,Ceftibuten versus trimethoprim-sulfamethoxazole for oral treatment of febrile urinary tract infection in children,Sweden,Hospital,Treatment for infection,Urinary tract,Urine,Trimethoprim-sulfamethoxazole,Oral,Trimethoprim-sulfamethoxazole,Gram negatives,0,NA,10,128,128,11,NA,4,4,,,,,,,,
15,18818954,Ceftibuten versus trimethoprim-sulfamethoxazole for oral treatment of febrile urinary tract infection in children,Sweden,Hospital,Treatment for infection,Urinary tract,Urine,Trimethoprim-sulfamethoxazole,Oral,Ceftibuten,Gram negatives,0,NA,10,255,255,11,NA,0,0,,,,,,,,
15,18818954,Ceftibuten versus trimethoprim-sulfamethoxazole for oral treatment of febrile urinary tract infection in children,Sweden,Hospital,Treatment for infection,Urinary tract,Urine,Ceftibuten,Oral,Trimethoprim-sulfamethoxazole,Gram negatives,0,NA,10,128,128,11,NA,1,1,,,,,,,,
15,18818954,Ceftibuten versus trimethoprim-sulfamethoxazole for oral treatment of febrile urinary tract infection in children,Sweden,Hospital,Treatment for infection,Urinary tract,Urine,Ceftibuten,Oral,Ceftibuten,Gram negatives,0,NA,10,255,255,11,NA,0,0,,,,,,,,
16,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Treatment for infection,Urinary tract,Urine,NA,NA,Fosfomycin trometamol,E coli,0,NA,0,260,260,1,NA,7,7,,,,,,,,
16,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Treatment for infection,Urinary tract,Urine,NA,NA,Fosfomycin trometamol,Enterobacter,0,NA,0,260,260,1,NA,3,3,,,,,,,,
16,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Treatment for infection,Urinary tract,Urine,NA,NA,Fosfomycin trometamol,Proteus,0,NA,0,260,260,1,NA,0,0,,,,,,,,
16,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Treatment for infection,Urinary tract,Urine,NA,NA,Fosfomycin trometamol,Klebsiella pneumoniae,0,NA,0,260,260,1,NA,0,0,,,,,,,,
16,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Treatment for infection,Urinary tract,Urine,NA,NA,Fosfomycin trometamol,Edwardsiella,0,NA,0,260,260,1,NA,0,0,,,,,,,,
16,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Treatment for infection,Urinary tract,Urine,NA,NA,Fosfomycin trometamol,Enterococcus,0,NA,0,260,260,1,NA,0,0,,,,,,,,
16,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Treatment for infection,Urinary tract,Urine,NA,NA,Fosfomycin trometamol,Staph saprophyticus,0,NA,0,260,260,1,NA,1,1,,,,,,,,
16,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Treatment for infection,Urinary tract,Urine,NA,NA,Imipenem,E coli,0,NA,0,260,260,1,NA,1,1,,,,,,,,
16,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Treatment for infection,Urinary tract,Urine,NA,NA,Imipenem,Enterobacter,0,NA,0,260,260,1,NA,0,0,,,,,,,,
16,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Treatment for infection,Urinary tract,Urine,NA,NA,Imipenem,Proteus,0,NA,0,260,260,1,NA,0,0,,,,,,,,
16,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Treatment for infection,Urinary tract,Urine,NA,NA,Imipenem,Klebsiella pneumoniae,0,NA,0,260,260,1,NA,0,0,,,,,,,,
16,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Treatment for infection,Urinary tract,Urine,NA,NA,Imipenem,Edwardsiella,0,NA,0,260,260,1,NA,0,0,,,,,,,,
16,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Treatment for infection,Urinary tract,Urine,NA,NA,Ceftriaxone,E coli,0,NA,0,260,260,1,NA,17,17,,,,,,,,
16,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Treatment for infection,Urinary tract,Urine,NA,NA,Ceftriaxone,Enterobacter,0,NA,0,260,260,1,NA,3,3,,,,,,,,
16,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Treatment for infection,Urinary tract,Urine,NA,NA,Ceftriaxone,Proteus,0,NA,0,260,260,1,NA,0,0,,,,,,,,
16,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Treatment for infection,Urinary tract,Urine,NA,NA,Ceftriaxone,Klebsiella pneumoniae,0,NA,0,260,260,1,NA,0,0,,,,,,,,
16,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Treatment for infection,Urinary tract,Urine,NA,NA,Ceftriaxone,Edwardsiella,0,NA,0,260,260,1,NA,0,0,,,,,,,,
16,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Treatment for infection,Urinary tract,Urine,NA,NA,Ciprofloxacin,E coli,0,NA,0,260,260,1,NA,48,48,,,,,,,,
16,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Treatment for infection,Urinary tract,Urine,NA,NA,Ciprofloxacin,Enterobacter,0,NA,0,260,260,1,NA,5,5,,,,,,,,
16,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Treatment for infection,Urinary tract,Urine,NA,NA,Ciprofloxacin,Proteus,0,NA,0,260,260,1,NA,1,1,,,,,,,,
16,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Treatment for infection,Urinary tract,Urine,NA,NA,Ciprofloxacin,Klebsiella pneumoniae,0,NA,0,260,260,1,NA,0,0,,,,,,,,
16,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Treatment for infection,Urinary tract,Urine,NA,NA,Ciprofloxacin,Edwardsiella,0,NA,0,260,260,1,NA,0,0,,,,,,,,
16,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Treatment for infection,Urinary tract,Urine,NA,NA,Ciprofloxacin,Staph saprophyticus,0,NA,0,260,260,1,NA,1,1,,,,,,,,
16,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Treatment for infection,Urinary tract,Urine,NA,NA,Levofloxacin,E coli,0,NA,0,260,260,1,NA,31,31,,,,,,,,
16,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Treatment for infection,Urinary tract,Urine,NA,NA,Levofloxacin,Enterobacter,0,NA,0,260,260,1,NA,3,3,,,,,,,,
16,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Treatment for infection,Urinary tract,Urine,NA,NA,Levofloxacin,Proteus,0,NA,0,260,260,1,NA,0,0,,,,,,,,
16,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Treatment for infection,Urinary tract,Urine,NA,NA,Levofloxacin,Klebsiella pneumoniae,0,NA,0,260,260,1,NA,0,0,,,,,,,,
16,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Treatment for infection,Urinary tract,Urine,NA,NA,Levofloxacin,Edwardsiella,0,NA,0,260,260,1,NA,0,0,,,,,,,,
16,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Treatment for infection,Urinary tract,Urine,NA,NA,Levofloxacin,Staph saprophyticus,0,NA,0,260,260,1,NA,1,1,,,,,,,,
16,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Treatment for infection,Urinary tract,Urine,NA,NA,Trimethoprim-sulfamethoxazole,E coli,0,NA,0,260,260,1,NA,66,66,,,,,,,,
16,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Treatment for infection,Urinary tract,Urine,NA,NA,Trimethoprim-sulfamethoxazole,Enterobacter,0,NA,0,260,260,1,NA,7,7,,,,,,,,
16,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Treatment for infection,Urinary tract,Urine,NA,NA,Trimethoprim-sulfamethoxazole,Proteus,0,NA,0,260,260,1,NA,1,1,,,,,,,,
16,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Treatment for infection,Urinary tract,Urine,NA,NA,Trimethoprim-sulfamethoxazole,Klebsiella pneumoniae,0,NA,0,260,260,1,NA,0,0,,,,,,,,
16,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Treatment for infection,Urinary tract,Urine,NA,NA,Trimethoprim-sulfamethoxazole,Staph saprophyticus,0,NA,0,260,260,1,NA,2,2,,,,,,,,
16,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Treatment for infection,Urinary tract,Urine,NA,NA,Gentamicin,E coli,0,NA,0,260,260,1,NA,50,50,,,,,,,,
16,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Treatment for infection,Urinary tract,Urine,NA,NA,Gentamicin,Enterobacter,0,NA,0,260,260,1,NA,6,6,,,,,,,,
16,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Treatment for infection,Urinary tract,Urine,NA,NA,Gentamicin,Proteus,0,NA,0,260,260,1,NA,1,1,,,,,,,,
16,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Treatment for infection,Urinary tract,Urine,NA,NA,Gentamicin,Klebsiella pneumoniae,0,NA,0,260,260,1,NA,0,0,,,,,,,,
16,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Treatment for infection,Urinary tract,Urine,NA,NA,Gentamicin,Enterococcus,0,NA,0,260,260,1,NA,0,0,,,,,,,,
16,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Treatment for infection,Urinary tract,Urine,NA,NA,Ampicillin,E coli,0,NA,0,260,260,1,NA,94,94,,,,,,,,
16,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Treatment for infection,Urinary tract,Urine,NA,NA,Ampicillin,Enterobacter,0,NA,0,260,260,1,NA,10,10,,,,,,,,
16,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Treatment for infection,Urinary tract,Urine,NA,NA,Ampicillin,Proteus,0,NA,0,260,260,1,NA,1,1,,,,,,,,
16,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Treatment for infection,Urinary tract,Urine,NA,NA,Ampicillin,Enterococcus,0,NA,0,260,260,1,NA,1,1,,,,,,,,
16,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Treatment for infection,Urinary tract,Urine,Fosfomycin trometamol,Oral,Fosfomycin trometamol,E coli,0,NA,1,130,130,8,NA,3,3,,,,,,,,
16,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Treatment for infection,Urinary tract,Urine,Fosfomycin trometamol,Oral,Fosfomycin trometamol,Proteus,0,NA,1,130,130,8,NA,1,1,,,,,,,,
16,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Treatment for infection,Urinary tract,Urine,Fosfomycin trometamol,Oral,Fosfomycin trometamol,Staph saprophyticus,0,NA,1,130,130,8,NA,1,1,,,,,,,,
16,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Treatment for infection,Urinary tract,Urine,,Oral,Ciprofloxacin,E coli,0,NA,5,130,130,8,NA,10,10,,,,,,,,
16,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Treatment for infection,Urinary tract,Urine,Ciprofloxacin,Oral,Ciprofloxacin,Enterobacter,0,NA,5,130,130,8,NA,2,2,,,,,,,,
17,21269858,Single-dose extended-release azithromycin versus a 10-day regimen of amoxicillin/clavulanate for the treatment of children with acute otitis media,Costa Rica and Dominican Republic,Outpatient,Treatment for infection,Inner ear,Respiratory tract,NA,NA,Penicillin,Pneumococcus,0,NA,0,565,565,1,NA,86,86,,,,,,,,
17,21269858,Single-dose extended-release azithromycin versus a 10-day regimen of amoxicillin/clavulanate for the treatment of children with acute otitis media,Costa Rica and Dominican Republic,Outpatient,Treatment for infection,Inner ear,Respiratory tract,NA,NA,Beta-lactamase producing,M catarhalis,0,NA,0,565,565,1,NA,58,58,,,,,,,,
17,21269858,Single-dose extended-release azithromycin versus a 10-day regimen of amoxicillin/clavulanate for the treatment of children with acute otitis media,Costa Rica and Dominican Republic,Outpatient,Treatment for infection,Inner ear,Respiratory tract,NA,NA,Oxacillin,Staph aureus,0,NA,0,565,565,1,NA,2,2,,,,,,,,
17,21269858,Single-dose extended-release azithromycin versus a 10-day regimen of amoxicillin/clavulanate for the treatment of children with acute otitis media,Costa Rica and Dominican Republic,Outpatient,Treatment for infection,Inner ear,Respiratory tract,NA,NA,Azithromycin,Pneumococcus,0,NA,0,282,282,1,NA,25,25,,,,,,,,
17,21269858,Single-dose extended-release azithromycin versus a 10-day regimen of amoxicillin/clavulanate for the treatment of children with acute otitis media,Costa Rica and Dominican Republic,Outpatient,Treatment for infection,Inner ear,Respiratory tract,NA,NA,Amox-clav,H influenzae,0,NA,0,565,565,1,NA,1,1,,,,,,,,
17,21269858,Single-dose extended-release azithromycin versus a 10-day regimen of amoxicillin/clavulanate for the treatment of children with acute otitis media,Costa Rica and Dominican Republic,Outpatient,Treatment for infection,Inner ear,Respiratory tract,NA,NA,Amox-clav,Pneumococcus,0,NA,0,283,283,1,NA,4,4,,,,,,,,
17,21269858,Single-dose extended-release azithromycin versus a 10-day regimen of amoxicillin/clavulanate for the treatment of children with acute otitis media,Costa Rica and Dominican Republic,Outpatient,Treatment for infection,Inner ear,Respiratory tract,NA,NA,Penicillin,Pneumococcus,0,NA,0,93,93,5,NA,18,18,,,,,,,,
17,21269858,Single-dose extended-release azithromycin versus a 10-day regimen of amoxicillin/clavulanate for the treatment of children with acute otitis media,Costa Rica and Dominican Republic,Outpatient,Treatment for infection,Inner ear,Respiratory tract,NA,NA,Beta-lactamase producing,M catarhalis,0,NA,0,93,93,5,NA,0,0,,,,,,,,
17,21269858,Single-dose extended-release azithromycin versus a 10-day regimen of amoxicillin/clavulanate for the treatment of children with acute otitis media,Costa Rica and Dominican Republic,Outpatient,Treatment for infection,Inner ear,Respiratory tract,NA,NA,Beta-lactamase producing,H influenzae,0,NA,0,93,93,5,NA,1,1,,,,,,,,
17,21269858,Single-dose extended-release azithromycin versus a 10-day regimen of amoxicillin/clavulanate for the treatment of children with acute otitis media,Costa Rica and Dominican Republic,Outpatient,Treatment for infection,Inner ear,Respiratory tract,NA,NA,Penicillin,Pneumococcus,0,NA,0,116,116,5,NA,16,16,,,,,,,,
17,21269858,Single-dose extended-release azithromycin versus a 10-day regimen of amoxicillin/clavulanate for the treatment of children with acute otitis media,Costa Rica and Dominican Republic,Outpatient,Treatment for infection,Inner ear,Respiratory tract,NA,NA,Beta-lactamase producing,H influenzae,0,NA,0,116,116,5,NA,1,1,,,,,,,,
18,26340658,Eradication therapy against pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis,Spain,Outpatient,Decolonisation,Respiratory tract,Respiratory tract,NA,NA,Tobramycin,Pseudomonas,0,NA,0,35,35,1,NA,0,0,,,,,,,,
18,26340658,Eradication therapy against pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis,Spain,Outpatient,Decolonisation,Respiratory tract,Respiratory tract,Tobramycin and ceftzidime,IV and inhaled,Tobramycin,Pseudomonas,0,NA,14,17,17,30,NA,0,0,,,,,,,,
18,26340658,Eradication therapy against pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis,Spain,Outpatient,Decolonisation,Respiratory tract,Respiratory tract,Tobramycin and ceftzidime,IV and inhaled,Tobramycin,Pseudomonas,0,NA,30,11,11,30,NA,0,0,,,,,,,,
18,26340658,Eradication therapy against pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis,Spain,Outpatient,Decolonisation,Respiratory tract,Respiratory tract,Tobramycin and ceftzidime,IV and inhaled,Tobramycin,Pseudomonas,0,NA,14,17,17,60,NA,0,0,,,,,,,,
18,26340658,Eradication therapy against pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis,Spain,Outpatient,Decolonisation,Respiratory tract,Respiratory tract,Tobramycin and ceftzidime,IV and inhaled,Tobramycin,Pseudomonas,0,NA,60,11,11,60,NA,0,0,,,,,,,,
18,26340658,Eradication therapy against pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis,Spain,Outpatient,Decolonisation,Respiratory tract,Respiratory tract,Tobramycin and ceftzidime,IV and inhaled,Tobramycin,Pseudomonas,0,NA,14,17,17,90,NA,0,0,,,,,,,,
18,26340658,Eradication therapy against pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis,Spain,Outpatient,Decolonisation,Respiratory tract,Respiratory tract,Tobramycin and ceftzidime,IV and inhaled,Tobramycin,Pseudomonas,0,NA,90,11,11,90,NA,0,0,,,,,,,,
18,26340658,Eradication therapy against pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis,Spain,Outpatient,Decolonisation,Respiratory tract,Respiratory tract,Tobramycin and ceftzidime,IV and inhaled,Tobramycin,Pseudomonas,0,NA,14,17,17,120,NA,0,0,,,,,,,,
18,26340658,Eradication therapy against pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis,Spain,Outpatient,Decolonisation,Respiratory tract,Respiratory tract,Tobramycin and ceftzidime,IV and inhaled,Tobramycin,Pseudomonas,0,NA,104,11,11,120,NA,0,0,,,,,,,,
18,26340658,Eradication therapy against pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis,Spain,Outpatient,Decolonisation,Respiratory tract,Respiratory tract,Tobramycin and ceftzidime,IV and inhaled,Tobramycin,Pseudomonas,0,NA,14,17,17,150,NA,0,0,,,,,,,,
18,26340658,Eradication therapy against pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis,Spain,Outpatient,Decolonisation,Respiratory tract,Respiratory tract,Tobramycin and ceftzidime,IV and inhaled,Tobramycin,Pseudomonas,0,NA,104,11,11,150,NA,0,0,,,,,,,,
18,26340658,Eradication therapy against pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis,Spain,Outpatient,Decolonisation,Respiratory tract,Respiratory tract,Tobramycin and ceftzidime,IV and inhaled,Tobramycin,Pseudomonas,0,NA,14,17,17,210,NA,0,0,,,,,,,,
18,26340658,Eradication therapy against pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis,Spain,Outpatient,Decolonisation,Respiratory tract,Respiratory tract,Tobramycin and ceftzidime,IV and inhaled,Tobramycin,Pseudomonas,0,NA,104,11,11,210,NA,0,0,,,,,,,,
18,26340658,Eradication therapy against pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis,Spain,Outpatient,Decolonisation,Respiratory tract,Respiratory tract,Tobramycin and ceftzidime,IV and inhaled,Tobramycin,Pseudomonas,0,NA,14,17,17,270,NA,0,0,,,,,,,,
18,26340658,Eradication therapy against pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis,Spain,Outpatient,Decolonisation,Respiratory tract,Respiratory tract,Tobramycin and ceftzidime,IV and inhaled,Tobramycin,Pseudomonas,0,NA,104,11,11,270,NA,0,0,,,,,,,,
18,26340658,Eradication therapy against pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis,Spain,Outpatient,Decolonisation,Respiratory tract,Respiratory tract,Tobramycin and ceftzidime,IV and inhaled,Tobramycin,Pseudomonas,0,NA,14,17,17,360,NA,0,0,,,,,,,,
18,26340658,Eradication therapy against pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis,Spain,Outpatient,Decolonisation,Respiratory tract,Respiratory tract,Tobramycin and ceftzidime,IV and inhaled,Tobramycin,Pseudomonas,0,NA,104,11,11,360,NA,0,0,,,,,,,,
18,26340658,Eradication therapy against pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis,Spain,Outpatient,Decolonisation,Respiratory tract,Respiratory tract,Tobramycin and ceftzidime,IV and inhaled,Tobramycin,Pseudomonas,0,NA,14,11,11,450,NA,0,0,,,,,,,,
18,26340658,Eradication therapy against pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis,Spain,Outpatient,Decolonisation,Respiratory tract,Respiratory tract,Tobramycin and ceftzidime,IV and inhaled,Tobramycin,Pseudomonas,0,NA,104,17,17,450,NA,0,0,,,,,,,,
19,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Prophylaxis,Urinary tract,Urine,NA,NA,Amoxicillin,E coli,0,NA,0,220,220,1,NA,100,100,,,,,,,,
19,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Prophylaxis,Urinary tract,Urine,NA,NA,Amoxicillin,E coli,0,NA,0,68,68,180,NA,41,41,,,,,,,,
19,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Prophylaxis,Urinary tract,Urine,"Nitrofurantoin, trimethoprim or cefalexin",Oral,Amoxicillin,E coli,0,NA,180,68,68,180,NA,32,32,,,,,,,,
19,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Prophylaxis,Urinary tract,Urine,NA,NA,Amoxicillin,E coli,0,NA,0,67,67,365,NA,35,35,,,,,,,,
19,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Prophylaxis,Urinary tract,Urine,"Nitrofurantoin, trimethoprim or cefalexin",Oral,Amoxicillin,E coli,0,NA,365,67,67,365,NA,37,37,,,,,,,,
19,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Prophylaxis,Urinary tract,Urine,NA,NA,Cefalexin,E coli,0,NA,0,225,225,1,NA,11,11,,,,,,,,
19,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Prophylaxis,Urinary tract,Urine,NA,NA,Cefalexin,E coli,0,NA,0,68,68,180,NA,5,5,,,,,,,,
19,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Prophylaxis,Urinary tract,Urine,"Nitrofurantoin, trimethoprim or cefalexin",Oral,Cefalexin,E coli,0,NA,180,67,67,180,NA,5,5,,,,,,,,
19,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Prophylaxis,Urinary tract,Urine,NA,NA,Cefalexin,E coli,0,NA,0,67,67,365,NA,6,6,,,,,,,,
19,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Prophylaxis,Urinary tract,Urine,"Nitrofurantoin, trimethoprim or cefalexin",Oral,Cefalexin,E coli,0,NA,365,75,75,365,NA,5,5,,,,,,,,
19,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Prophylaxis,Urinary tract,Urine,NA,NA,Ciprofloxacin,E coli,0,NA,0,219,219,1,NA,5,,,,,,,,,
19,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Prophylaxis,Urinary tract,Urine,NA,NA,Ciprofloxacin,E coli,0,NA,0,68,68,180,NA,5,,,,,,,,,
19,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Prophylaxis,Urinary tract,Urine,"Nitrofurantoin, trimethoprim or cefalexin",Oral,Ciprofloxacin,E coli,0,NA,180,68,68,180,NA,5,,,,,,,,,
19,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Prophylaxis,Urinary tract,Urine,NA,NA,Ciprofloxacin,E coli,0,NA,0,67,67,365,NA,5,,,,,,,,,
19,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Prophylaxis,Urinary tract,Urine,"Nitrofurantoin, trimethoprim or cefalexin",Oral,Ciprofloxacin,E coli,0,NA,365,67,67,365,NA,5,,,,,,,,,
19,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Prophylaxis,Urinary tract,Urine,NA,NA,Trimethoprim-sulfamethoxazole,E coli,0,NA,0,218,218,1,NA,58,58,,,,,,,,
19,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Prophylaxis,Urinary tract,Urine,NA,NA,Trimethoprim-sulfamethoxazole,E coli,0,NA,0,68,68,180,NA,16,16,,,,,,,,
19,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Prophylaxis,Urinary tract,Urine,"Nitrofurantoin, trimethoprim or cefalexin",Oral,Trimethoprim-sulfamethoxazole,E coli,0,NA,180,68,68,180,NA,18,18,,,,,,,,
19,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Prophylaxis,Urinary tract,Urine,NA,NA,Trimethoprim-sulfamethoxazole,E coli,0,NA,0,67,67,365,NA,25,25,,,,,,,,
19,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Prophylaxis,Urinary tract,Urine,"Nitrofurantoin, trimethoprim or cefalexin",Oral,Trimethoprim-sulfamethoxazole,E coli,0,NA,365,67,67,365,NA,17,17,,,,,,,,
19,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Prophylaxis,Urinary tract,Urine,NA,NA,Amox-clav,E coli,0,NA,0,217,217,1,NA,14,14,,,,,,,,
19,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Prophylaxis,Urinary tract,Urine,NA,NA,Amox-clav,E coli,0,NA,0,68,68,180,NA,7,7,,,,,,,,
19,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Prophylaxis,Urinary tract,Urine,"Nitrofurantoin, trimethoprim or cefalexin",Oral,Amox-clav,E coli,0,NA,180,67,67,180,NA,2,2,,,,,,,,
19,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Prophylaxis,Urinary tract,Urine,NA,NA,Amox-clav,E coli,0,NA,0,67,67,365,NA,5,5,,,,,,,,
19,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Prophylaxis,Urinary tract,Urine,"Nitrofurantoin, trimethoprim or cefalexin",Oral,Amox-clav,E coli,0,NA,365,75,75,365,NA,5,5,,,,,,,,
19,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Prophylaxis,Urinary tract,Urine,NA,NA,Mecillinam,E coli,0,NA,0,215,215,1,NA,5,5,,,,,,,,
19,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Prophylaxis,Urinary tract,Urine,NA,NA,Mecillinam,E coli,0,NA,0,68,68,180,NA,0,0,,,,,,,,
19,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Prophylaxis,Urinary tract,Urine,"Nitrofurantoin, trimethoprim or cefalexin",Oral,Mecillinam,E coli,0,NA,180,68,68,180,NA,1,1,,,,,,,,
19,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Prophylaxis,Urinary tract,Urine,NA,NA,Mecillinam,E coli,0,NA,0,67,67,365,NA,2,2,,,,,,,,
19,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Prophylaxis,Urinary tract,Urine,"Nitrofurantoin, trimethoprim or cefalexin",Oral,Mecillinam,E coli,0,NA,365,66,66,365,NA,0,0,,,,,,,,
19,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Prophylaxis,Urinary tract,Urine,NA,NA,Nitrofurantoin,E coli,0,NA,0,215,215,1,NA,1,1,,,,,,,,
19,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Prophylaxis,Urinary tract,Urine,NA,NA,Nitrofurantoin,E coli,0,NA,0,68,68,180,NA,1,1,,,,,,,,
19,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Prophylaxis,Urinary tract,Urine,"Nitrofurantoin, trimethoprim or cefalexin",Oral,Nitrofurantoin,E coli,0,NA,180,68,68,180,NA,4,4,,,,,,,,
19,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Prophylaxis,Urinary tract,Urine,NA,NA,Nitrofurantoin,E coli,0,NA,0,67,67,365,NA,3,3,,,,,,,,
19,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Prophylaxis,Urinary tract,Urine,"Nitrofurantoin, trimethoprim or cefalexin",Oral,Nitrofurantoin,E coli,0,NA,365,66,66,365,NA,2,2,,,,,,,,
19,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Prophylaxis,Urinary tract,Urine,NA,NA,Trimethoprim,E coli,0,NA,0,215,215,1,NA,67,67,,,,,,,,
19,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Prophylaxis,Urinary tract,Urine,NA,NA,Trimethoprim,E coli,0,NA,0,68,68,180,NA,31,31,,,,,,,,
19,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Prophylaxis,Urinary tract,Urine,"Nitrofurantoin, trimethoprim or cefalexin",Oral,Trimethoprim,E coli,0,NA,180,68,68,180,NA,20,20,,,,,,,,
19,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Prophylaxis,Urinary tract,Urine,NA,NA,Trimethoprim,E coli,0,NA,0,67,67,365,NA,31,31,,,,,,,,
19,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Prophylaxis,Urinary tract,Urine,"Nitrofurantoin, trimethoprim or cefalexin",Oral,Trimethoprim,E coli,0,NA,365,66,66,365,NA,20,20,,,,,,,,
20,31821452,Increased risk of acquisition and transmission of ESBL-producing Enterobacteriaceae in malnourished children exposed to amoxicillin,Nigeria,Outpatient,Prevention or treatment of non-infectious diseases,Gut,Gut,NA,NA,ESBL-producing ,Enterobacteriaceae,0,NA,0,468,468,1,NA,141,141,,,,,,,,
20,31821452,Increased risk of acquisition and transmission of ESBL-producing Enterobacteriaceae in malnourished children exposed to amoxicillin,Nigeria,Outpatient,Prevention or treatment of non-infectious diseases,Gut,Gut,NA,NA,ESBL-producing ,Enterobacteriaceae,0,NA,0,161,161,7,NA,52,52,,,,,,,,
20,31821452,Increased risk of acquisition and transmission of ESBL-producing Enterobacteriaceae in malnourished children exposed to amoxicillin,Nigeria,Outpatient,Prevention or treatment of non-infectious diseases,Gut,Gut,Amoxicillin,Oral,ESBL-producing ,Enterobacteriaceae,0,NA,7,147,147,7,NA,79,79,,,,,,,,
20,31821452,Increased risk of acquisition and transmission of ESBL-producing Enterobacteriaceae in malnourished children exposed to amoxicillin,Nigeria,Outpatient,Prevention or treatment of non-infectious diseases,Gut,Gut,NA,NA,ESBL-producing ,Enterobacteriaceae,0,NA,0,117,117,28,NA,16,16,,,,,,,,
20,31821452,Increased risk of acquisition and transmission of ESBL-producing Enterobacteriaceae in malnourished children exposed to amoxicillin,Nigeria,Outpatient,Prevention or treatment of non-infectious diseases,Gut,Gut,Amoxicillin,Oral,ESBL-producing ,Enterobacteriaceae,0,NA,7,96,96,28,NA,8,8,,,,,,,,
21,30853250,"Efficacy and safety of intravenous ceftriaxone at home versus intravenous flucloxacillin in hospital for children with cellulitis (CHOICE): a single-centre, open-label, randomised, controlled, non-inferiority trial",Australia,Outpatient,Treatment for infection,Skin and soft tissue,Gut,NA,NA,ESBL-producing ,Enterobacteriaceae,0,NA,0,90,90,1,NA,11,11,,,,,,,,
21,30853250,"Efficacy and safety of intravenous ceftriaxone at home versus intravenous flucloxacillin in hospital for children with cellulitis (CHOICE): a single-centre, open-label, randomised, controlled, non-inferiority trial",Australia,Outpatient,Treatment for infection,Skin and soft tissue,Respiratory tract,NA,NA,Meticillin,Staph aureus,0,NA,0,131,131,1,NA,0,0,,,,,,,,
21,30853250,"Efficacy and safety of intravenous ceftriaxone at home versus intravenous flucloxacillin in hospital for children with cellulitis (CHOICE): a single-centre, open-label, randomised, controlled, non-inferiority trial",Australia,Outpatient,Treatment for infection,Skin and soft tissue,Gut,Flucloxacillin,IV,ESBL-producing ,Enterobacteriaceae,0,NA,8,33,33,10,NA,4,4,,,,,,,,
21,30853250,"Efficacy and safety of intravenous ceftriaxone at home versus intravenous flucloxacillin in hospital for children with cellulitis (CHOICE): a single-centre, open-label, randomised, controlled, non-inferiority trial",Australia,Outpatient,Treatment for infection,Skin and soft tissue,Respiratory tract,Flucloxacillin,IV,Meticillin,Staph aureus,0,NA,8,35,35,10,NA,0,0,,,,,,,,
21,30853250,"Efficacy and safety of intravenous ceftriaxone at home versus intravenous flucloxacillin in hospital for children with cellulitis (CHOICE): a single-centre, open-label, randomised, controlled, non-inferiority trial",Australia,Hospital,Treatment for infection,Skin and soft tissue,Gut,Ceftiaxone,IV,ESBL-producing ,Enterobacteriaceae,0,NA,8,48,48,10,NA,10,10,,,,,,,,
21,30853250,"Efficacy and safety of intravenous ceftriaxone at home versus intravenous flucloxacillin in hospital for children with cellulitis (CHOICE): a single-centre, open-label, randomised, controlled, non-inferiority trial",Australia,Hospital,Treatment for infection,Skin and soft tissue,Respiratory tract,Ceftiaxone,IV,Meticillin,Staph aureus,0,NA,8,49,49,10,NA,0,0,,,,,,,,
21,30853250,"Efficacy and safety of intravenous ceftriaxone at home versus intravenous flucloxacillin in hospital for children with cellulitis (CHOICE): a single-centre, open-label, randomised, controlled, non-inferiority trial",Australia,Outpatient,Treatment for infection,Skin and soft tissue,Gut,Flucloxacillin,IV,ESBL-producing ,Enterobacteriaceae,0,NA,8,35,35,90,NA,7,7,,,,,,,,
21,30853250,"Efficacy and safety of intravenous ceftriaxone at home versus intravenous flucloxacillin in hospital for children with cellulitis (CHOICE): a single-centre, open-label, randomised, controlled, non-inferiority trial",Australia,Outpatient,Treatment for infection,Skin and soft tissue,Respiratory tract,Flucloxacillin,IV,Meticillin,Staph aureus,0,NA,8,34,34,90,NA,0,0,,,,,,,,
21,30853250,"Efficacy and safety of intravenous ceftriaxone at home versus intravenous flucloxacillin in hospital for children with cellulitis (CHOICE): a single-centre, open-label, randomised, controlled, non-inferiority trial",Australia,Hospital,Treatment for infection,Skin and soft tissue,Gut,Ceftiaxone,IV,ESBL-producing ,Enterobacteriaceae,0,NA,8,44,44,90,NA,8,8,,,,,,,,
21,30853250,"Efficacy and safety of intravenous ceftriaxone at home versus intravenous flucloxacillin in hospital for children with cellulitis (CHOICE): a single-centre, open-label, randomised, controlled, non-inferiority trial",Australia,Hospital,Treatment for infection,Skin and soft tissue,Respiratory tract,Ceftiaxone,IV,Meticillin,Staph aureus,0,NA,8,54,54,90,NA,1,1,,,,,,,,
22,31867616,Weekly Sequential Antibioprophylaxis for Recurrent Urinary Tract Infections among Patients with Neurogenic Bladder: A Randomized Controlled Trial,France,Outpatient,Prophylaxis,Urinary tract,Gut,NA,NA,ESBL-producing ,Enterobacteriaceae,0,NA,0,42,42,1,NA,8,8,,,,,,,,
22,31867616,Weekly Sequential Antibioprophylaxis for Recurrent Urinary Tract Infections among Patients with Neurogenic Bladder: A Randomized Controlled Trial,France,Outpatient,Prophylaxis,Urinary tract,Respiratory tract,NA,NA,Meticillin,Staph aureus,0,NA,0,45,45,1,NA,6,6,,,,,,,,
22,31867616,Weekly Sequential Antibioprophylaxis for Recurrent Urinary Tract Infections among Patients with Neurogenic Bladder: A Randomized Controlled Trial,France,Outpatient,Prophylaxis,Urinary tract,Gut,NA,NA,ESBL-producing ,Enterobacteriaceae,0,NA,0,18,18,180,NA,1,1,,,,,,,,
22,31867616,Weekly Sequential Antibioprophylaxis for Recurrent Urinary Tract Infections among Patients with Neurogenic Bladder: A Randomized Controlled Trial,France,Outpatient,Prophylaxis,Urinary tract,Respiratory tract,NA,NA,Meticillin,Staph aureus,0,NA,0,16,16,180,NA,0,0,,,,,,,,
22,31867616,Weekly Sequential Antibioprophylaxis for Recurrent Urinary Tract Infections among Patients with Neurogenic Bladder: A Randomized Controlled Trial,France,Outpatient,Prophylaxis,Urinary tract,Gut,Fosfomycin trometamol or trimethoprim-sulfamethoxazole or amox-clav or cefixim or furadantin ,Oral,ESBL-producing ,Enterobacteriaceae,0,NA,Once   in alternate weeks,18,18,180,NA,1,1,,,,,,,,
22,31867616,Weekly Sequential Antibioprophylaxis for Recurrent Urinary Tract Infections among Patients with Neurogenic Bladder: A Randomized Controlled Trial,France,Outpatient,Prophylaxis,Urinary tract,Respiratory tract,Fosfomycin trometamol or trimethoprim-sulfamethoxazole or amox-clav or cefixim or furadantin ,Oral,Meticillin,Staph aureus,0,NA,Once   in alternate weeks,16,16,180,NA,0,0,,,,,,,,
23,32130261,Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): A randomised controlled trial,Europe,ICU,Treatment for infection,Bloodstream,Gut,NA,NA,Carbapenem,Gram negatives,0,NA,0,195,195,1,NA,0,0,,,,,,,,
23,32130261,Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): A randomised controlled trial,Europe,ICU,Treatment for infection,Bloodstream,Gut,Meropenem,IV,Carbapenem,Gram negatives,0,NA,8,101,101,28,NA,19,19,,,,,,,,
23,32130261,Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): A randomised controlled trial,Europe,ICU,Treatment for infection,Bloodstream,Gut,Ampicillin+gentamicin or cefotaxime+gentamicin,IV,Carbapenem,Gram negatives,0,NA,7,94,94,28,NA,7,7,,,,,,,,
24,32267724,"Targeted retreatment of incompletely recovered chronic obstructive pulmonary disease exacerbations with ciprofloxacin a double-blind, randomized, placebo-controlled, multicenter, phase III clinical trial",UK,Outpatient,Treatment for infection,Respiratory tract,Respiratory tract,NA,NA,Ciprofloxacin,Bacteria,0,NA,0,47,47,1,NA,1,1,,,,,,,,
24,32267724,"Targeted retreatment of incompletely recovered chronic obstructive pulmonary disease exacerbations with ciprofloxacin a double-blind, randomized, placebo-controlled, multicenter, phase III clinical trial",UK,Outpatient,Treatment for infection,Respiratory tract,Respiratory tract,NA,NA,Ciprofloxacin,Bacteria,0,NA,0,17,17,90,NA,1,1,,,,,,,,
24,32267724,"Targeted retreatment of incompletely recovered chronic obstructive pulmonary disease exacerbations with ciprofloxacin a double-blind, randomized, placebo-controlled, multicenter, phase III clinical trial",UK,Outpatient,Treatment for infection,Respiratory tract,Respiratory tract,Ciprofloxacin,Oral,Ciprofloxacin,Bacteria,0,NA,7,16,16,90,NA,0,0,,,,,,,,
25,32539786,Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: Results of a multicenter randomized placebo-controlled clinical trial,Netherlands,Hospital,Decolonisation,Gut,Gut,NA,NA,ESBL-producing ,Enterobacteriaceae,0,NA,0,78,78,1,NA,3,3,,,,,,,,
25,32539786,Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: Results of a multicenter randomized placebo-controlled clinical trial,Netherlands,Hospital,Decolonisation,Gut,Gut,NA,NA,Carbapenem,Gram negatives,0,NA,0,78,78,1,NA,3,3,,,,,,,,
25,32539786,Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: Results of a multicenter randomized placebo-controlled clinical trial,Netherlands,Hospital,Decolonisation,Gut,Gut,NA,NA,Tobramycin,Gram negatives,0,NA,0,78,78,1,NA,26,26,,,,,,,,
25,32539786,Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: Results of a multicenter randomized placebo-controlled clinical trial,Netherlands,Hospital,Decolonisation,Gut,Gut,NA,NA,Colistin,Gram negatives,0,NA,0,78,78,1,NA,13,13,,,,,,,,
25,32539786,Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: Results of a multicenter randomized placebo-controlled clinical trial,Netherlands,Hospital,Decolonisation,Gut,Gut,NA,NA,ESBL-producing ,Enterobacteriaceae,0,NA,0,28,28,30,NA,1,1,,,,,,,,
25,32539786,Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: Results of a multicenter randomized placebo-controlled clinical trial,Netherlands,Hospital,Decolonisation,Gut,Gut,NA,NA,Carbapenem,Gram negatives,0,NA,0,28,28,30,NA,1,1,,,,,,,,
25,32539786,Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: Results of a multicenter randomized placebo-controlled clinical trial,Netherlands,Hospital,Decolonisation,Gut,Gut,NA,NA,Tobramycin,Gram negatives,0,NA,0,28,28,30,NA,10,10,,,,,,,,
25,32539786,Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: Results of a multicenter randomized placebo-controlled clinical trial,Netherlands,Hospital,Decolonisation,Gut,Gut,NA,NA,Colistin,Gram negatives,0,NA,0,28,28,30,NA,4,4,,,,,,,,
25,32539786,Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: Results of a multicenter randomized placebo-controlled clinical trial,Netherlands,Hospital,Decolonisation,Gut,Gut,Combination (tobramycin and colistin sulphate),Oral,ESBL-producing ,Enterobacteriaceae,0,NA,3,34,34,30,NA,1,1,,,,,,,,
25,32539786,Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: Results of a multicenter randomized placebo-controlled clinical trial,Netherlands,Hospital,Decolonisation,Gut,Gut,Combination (tobramycin and colistin sulphate),Oral,Carbapenem,Gram negatives,0,NA,3,34,34,30,NA,0,0,,,,,,,,
25,32539786,Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: Results of a multicenter randomized placebo-controlled clinical trial,Netherlands,Hospital,Decolonisation,Gut,Gut,Combination (tobramycin and colistin sulphate),Oral,Tobramycin,Gram negatives,0,NA,3,34,34,30,NA,15,15,,,,,,,,
25,32539786,Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: Results of a multicenter randomized placebo-controlled clinical trial,Netherlands,Hospital,Decolonisation,Gut,Gut,Combination (tobramycin and colistin sulphate),Oral,Colistin,Gram negatives,0,NA,3,34,34,30,NA,4,4,,,,,,,,
25,32539786,Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: Results of a multicenter randomized placebo-controlled clinical trial,Netherlands,Hospital,Decolonisation,Gut,Gut,NA,NA,ESBL-producing ,Enterobacteriaceae,0,NA,0,78,78,1,NA,3,3,,,,,,,,
25,32539786,Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: Results of a multicenter randomized placebo-controlled clinical trial,Netherlands,Hospital,Decolonisation,Gut,Gut,NA,NA,Carbapenem,Gram negatives,0,NA,0,78,78,1,NA,3,3,,,,,,,,
25,32539786,Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: Results of a multicenter randomized placebo-controlled clinical trial,Netherlands,Hospital,Decolonisation,Gut,Gut,NA,NA,Tobramycin,Gram negatives,0,NA,0,78,78,1,NA,26,26,,,,,,,,
25,32539786,Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: Results of a multicenter randomized placebo-controlled clinical trial,Netherlands,Hospital,Decolonisation,Gut,Gut,NA,NA,Colistin,Gram negatives,0,NA,0,78,78,1,NA,13,13,,,,,,,,
25,32539786,Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: Results of a multicenter randomized placebo-controlled clinical trial,Netherlands,Hospital,Decolonisation,Gut,Gut,NA,NA,ESBL-producing ,Enterobacteriaceae,0,NA,0,28,28,30,NA,1,1,,,,,,,,
25,32539786,Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: Results of a multicenter randomized placebo-controlled clinical trial,Netherlands,Hospital,Decolonisation,Gut,Gut,NA,NA,Carbapenem,Gram negatives,0,NA,0,28,28,30,NA,1,1,,,,,,,,
25,32539786,Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: Results of a multicenter randomized placebo-controlled clinical trial,Netherlands,Hospital,Decolonisation,Gut,Gut,NA,NA,Tobramycin,Gram negatives,0,NA,0,28,28,30,NA,10,10,,,,,,,,
25,32539786,Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: Results of a multicenter randomized placebo-controlled clinical trial,Netherlands,Hospital,Decolonisation,Gut,Gut,NA,NA,Colistin,Gram negatives,0,NA,0,28,28,30,NA,4,4,,,,,,,,
25,32539786,Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: Results of a multicenter randomized placebo-controlled clinical trial,Netherlands,Hospital,Decolonisation,Gut,Gut,Combination (tobramycin and colistin sulphate),Oral,ESBL-producing ,Enterobacteriaceae,0,NA,3,34,34,30,NA,1,1,,,,,,,,
25,32539786,Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: Results of a multicenter randomized placebo-controlled clinical trial,Netherlands,Hospital,Decolonisation,Gut,Gut,Combination (tobramycin and colistin sulphate),Oral,Carbapenem,Gram negatives,0,NA,3,34,34,30,NA,0,0,,,,,,,,
25,32539786,Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: Results of a multicenter randomized placebo-controlled clinical trial,Netherlands,Hospital,Decolonisation,Gut,Gut,Combination (tobramycin and colistin sulphate),Oral,Tobramycin,Gram negatives,0,NA,3,34,34,30,NA,15,15,,,,,,,,
25,32539786,Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: Results of a multicenter randomized placebo-controlled clinical trial,Netherlands,Hospital,Decolonisation,Gut,Gut,Combination (tobramycin and colistin sulphate),Oral,Colistin,Gram negatives,0,NA,3,34,34,30,NA,4,4,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,NA,NA,Ciprofloxacin,Klebsiella pneumoniae,0,NA,0,207,207,1,NA,1,1,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,NA,NA,Ciprofloxacin,Acinectobacter baumannii,0,NA,0,207,207,1,NA,1,1,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,NA,NA,Ciprofloxacin,Staph aureus,0,NA,0,207,207,1,NA,2,2,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,NA,NA,Ciprofloxacin,Enterococcus,0,NA,0,207,207,1,NA,4,4,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,NA,NA,Gentamicin,E coli,0,NA,0,207,207,1,NA,1,1,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,NA,NA,Gentamicin,Klebsiella pneumoniae,0,NA,0,207,207,1,NA,1,1,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,NA,NA,Gentamicin,Pseudomonas,0,NA,0,207,207,1,NA,3,3,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,NA,NA,Gentamicin,Staph aureus,0,NA,0,207,207,1,NA,1,1,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,NA,NA,Gentamicin,Enterococcus,0,NA,0,207,207,1,NA,33,33,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,NA,NA,Polymyxin,E coli,0,NA,0,207,207,1,NA,1,1,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,NA,NA,Polymyxin,Proteus,0,NA,0,207,207,1,NA,10,10,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,NA,NA,Polymyxin,Other Enterobacteriaceae,0,NA,0,207,207,1,NA,2,2,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,NA,NA,Polymyxin,Pseudomonas,0,NA,0,207,207,1,NA,2,2,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,"Combination (ciprofloxacin, gentamicin and polymyxin)",Oral and IV,Ciprofloxacin,Klebsiella pneumoniae,0,NA,4,175,175,1,NA,1,1,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,"Combination (ciprofloxacin, gentamicin and polymyxin)",Oral and IV,Ciprofloxacin,Other Enterobacteriaceae,0,NA,4,175,175,1,NA,1,1,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,"Combination (ciprofloxacin, gentamicin and polymyxin)",Oral and IV,Ciprofloxacin,Staph aureus,0,NA,4,175,175,1,NA,3,3,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,"Combination (ciprofloxacin, gentamicin and polymyxin)",Oral and IV,Ciprofloxacin,Enterococcus,0,NA,4,175,175,1,NA,13,13,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,"Combination (ciprofloxacin, gentamicin and polymyxin)",Oral and IV,Gentamicin,E coli,0,NA,4,175,175,1,NA,1,1,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,"Combination (ciprofloxacin, gentamicin and polymyxin)",Oral and IV,Gentamicin,Klebsiella pneumoniae,0,NA,4,175,175,1,NA,1,1,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,"Combination (ciprofloxacin, gentamicin and polymyxin)",Oral and IV,Gentamicin,Other Enterobacteriaceae,0,NA,4,175,175,1,NA,1,1,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,"Combination (ciprofloxacin, gentamicin and polymyxin)",Oral and IV,Gentamicin,Pseudomonas,0,NA,4,175,175,1,NA,3,3,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,"Combination (ciprofloxacin, gentamicin and polymyxin)",Oral and IV,Gentamicin,Acinectobacter baumannii,0,NA,4,175,175,1,NA,2,2,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,"Combination (ciprofloxacin, gentamicin and polymyxin)",Oral and IV,Gentamicin,Staph aureus,0,NA,4,175,175,1,NA,6,6,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,"Combination (ciprofloxacin, gentamicin and polymyxin)",Oral and IV,Gentamicin,Enterococcus,0,NA,4,175,175,1,NA,53,53,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,"Combination (ciprofloxacin, gentamicin and polymyxin)",Oral and IV,Polymyxin,Proteus,0,NA,4,175,175,1,NA,9,9,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,"Combination (ciprofloxacin, gentamicin and polymyxin)",Oral and IV,Polymyxin,Other Enterobacteriaceae,0,NA,4,175,175,1,NA,2,2,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,"Combination (ciprofloxacin, gentamicin and polymyxin)",Oral and IV,Polymyxin,Pseudomonas,0,NA,4,175,175,1,NA,5,5,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,"Combination (ciprofloxacin, gentamicin and polymyxin)",Oral and IV,Oxacillin,Staph aureus,0,NA,4,175,175,1,NA,2,2,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,"Combination (ciprofloxacin, gentamicin and polymyxin)",Oral and IV,Polymyxin,Proteus,0,NA,4,144,144,1,NA,6,6,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,"Combination (ciprofloxacin, gentamicin and polymyxin)",Oral and IV,Polymyxin,Pseudomonas,0,NA,4,144,144,1,NA,4,4,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,"Combination (ciprofloxacin, gentamicin and polymyxin)",Oral and IV,Oxacillin,Staph aureus,0,NA,4,144,144,1,NA,1,1,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,NA,NA,Ciprofloxacin,Klebsiella pneumoniae,0,NA,0,203,203,1,NA,1,1,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,NA,NA,Ciprofloxacin,Staph aureus,0,NA,0,203,203,1,NA,2,2,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,NA,NA,Ciprofloxacin,Enterococcus,0,NA,0,203,203,1,NA,5,5,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,NA,NA,Gentamicin,E coli,0,NA,0,203,203,1,NA,2,2,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,NA,NA,Gentamicin,Acinectobacter baumannii,0,NA,0,203,203,1,NA,2,2,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,NA,NA,Gentamicin,Staph aureus,0,NA,0,203,203,1,NA,2,2,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,NA,NA,Gentamicin,Enterococcus,0,NA,0,203,203,1,NA,39,39,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,NA,NA,Polymyxin,E coli,0,NA,0,203,203,1,NA,2,2,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,NA,NA,Polymyxin,Proteus,0,NA,0,203,203,1,NA,15,15,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,NA,NA,Polymyxin,Other Enterobacteriaceae,0,NA,0,203,203,1,NA,3,3,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,NA,NA,Polymyxin,Pseudomonas,0,NA,0,203,203,1,NA,2,2,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,NA,NA,Oxacillin,Staph aureus,0,NA,0,203,203,1,NA,1,1,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,NA,NA,Ciprofloxacin,Klebsiella pneumoniae,0,NA,0,171,171,28,NA,1,1,Follow up times not reported,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,NA,NA,Ciprofloxacin,Pseudomonas,0,NA,0,171,171,28,NA,2,2,"Quantitative cultures of the oropharynx, trachea, and stomach were obtained from each patient on admission and according to the following schedule: Days 2 or 3, 5 or 6, 8 or 9, 11 or 12, 14 or 15, 20 or 21, and 27 or 28. This was followed by two to three ",,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,NA,NA,Ciprofloxacin,Acinectobacter baumannii,0,NA,0,171,171,28,NA,2,2,"The median length of ICU stay was 10 days for both groups, and the interquartile ranges between the first and third quartiles were 5 to 19 days (maximum, 120) and 5 to 23 days (maximum, 171) for the prophylaxis and placebo group, respectively.",,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,NA,NA,Ciprofloxacin,Staph aureus,0,NA,0,171,171,28,NA,9,9,Assume during study = 28 days ,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,NA,NA,Ciprofloxacin,Enterococcus,0,NA,0,171,171,28,NA,18,18,Assume end of study = 56 days,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,NA,NA,Gentamicin,Proteus,0,NA,0,171,171,28,NA,1,1,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,NA,NA,Gentamicin,Other Enterobacteriaceae,0,NA,0,171,171,28,NA,1,1,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,NA,NA,Gentamicin,Pseudomonas,0,NA,0,171,171,28,NA,10,10,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,NA,NA,Gentamicin,Staph aureus,0,NA,0,171,171,28,NA,11,11,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,NA,NA,Gentamicin,Enterococcus,0,NA,0,171,171,28,NA,88,88,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,NA,NA,Polymyxin,E coli,0,NA,0,171,171,28,NA,2,2,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,NA,NA,Polymyxin,Klebsiella pneumoniae,0,NA,0,171,171,28,NA,2,2,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,NA,NA,Polymyxin,Proteus,0,NA,0,171,171,28,NA,29,29,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,NA,NA,Polymyxin,Other Enterobacteriaceae,0,NA,0,171,171,28,NA,3,3,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,NA,NA,Polymyxin,Pseudomonas,0,NA,0,171,171,28,NA,1,1,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,NA,NA,Oxacillin,Staph aureus,0,NA,0,171,171,28,NA,7,7,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,NA,NA,Ciprofloxacin,Staph aureus,0,NA,0,138,138,56,NA,4,4,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,NA,NA,Ciprofloxacin,Enterococcus,0,NA,0,138,138,56,NA,3,3,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,NA,NA,Gentamicin,Pseudomonas,0,NA,0,138,138,56,NA,3,3,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,NA,NA,Gentamicin,Staph aureus,0,NA,0,138,138,56,NA,4,4,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,NA,NA,Gentamicin,Enterococcus,0,NA,0,138,138,56,NA,30,30,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,NA,NA,Polymyxin,Proteus,0,NA,0,138,138,56,NA,10,10,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,NA,NA,Polymyxin,Other Enterobacteriaceae,0,NA,0,138,138,56,NA,2,2,,,,,,,,
26,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Decolonisation,Gut,Gut or respiratory tract,NA,NA,Polymyxin,Staph aureus,0,NA,0,138,138,56,NA,1,1,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,,,,,,,,